+Vote!
PR News Wire (Free subscription) | 17/09/2008
DEERFIELD, Ill., Sept. 17 /PRNewswire-FirstCall/ -- Baxter
International (NYSE: ), will host a quarterly conference call to discuss
its third quarter 2008 financial results on Thursday, October 16, 2008, at
8:30 a.m. Eastern Time (7:30 a.m. Central Time). To access the call, please
dial 866- 238-0637 (domestic) or 703-639-1156 (international). Please dial
into the call at least ten minutes prior to...
+Vote!
Pharmalot (Free subscription) | 31/07/2008
For the first time, the agency has conclusively linked patient deaths to a foreign substance found in specific lots of the drug made by Baxter International, The Chicago Tribune reports. The FDA completed its review of 93 death reports related to heparin that were received from January 1 to March 31, a period when there was [...]
+Vote!
Chicago Tribune (Free subscription) | 31/07/2008
Alzheimer's candidate used for other diseases As the pharmaceutical industry enters a critical phase before possible U.S. approval of a new Alzheimer's disease treatment, Deerfield-based Baxter International Inc. is among the firms with a drug showing promise to combat the disorder.
1Vote!
Red Orbit (Free subscription) | 31/07/2008
CHICAGO _ As the pharmaceutical industry enters a critical phase before possible U.S. approval for an Alzheimer's treatment, Baxter International Inc. is among the firms with a drug showing promise to combat the disease.
+Vote!
Chicago Tribune (Free subscription) | 30/07/2008
A Baxter International Inc. drug used to treat immune system disorders shows promise as a treatment for Alzheimer's disease in a small-scale study the company has figured in its decision to now move to a critical, larger final stage.
+Vote!
Ph articles (Free subscription) | 30/07/2008
CHICAGO (Reuters) - Alzheimer's disease patients treated with Baxter International Inc's Gammagard for nine months maintained cognitive function and in some cases improved it, according to an interim analysis of data from a small study. "If successful, it should actually transmute the long-term course of the illness, and the effects should be steadfast for a very slow proper time," Dr. Norman Relkin,...
+Vote!
Reuters (Free subscription) | 30/07/2008
CHICAGO (Reuters) - Alzheimer's disease patients treated with Baxter International Inc's Gammagard for nine months maintained cognitive function and in some cases improved it, according to an interim analysis of data from a small study.
+Vote!
Chicago Tribune (Free subscription) | 30/07/2008
FDA: 3 fatalities linked to material in Baxter product The U.S. Food and Drug Administration, for the first time, has conclusively linked deaths of patients infused with the blood thinner heparin to a foreign substance found in specific lots of the drug made by Deerfield-based Baxter International Inc.
+Vote!
Market Watch (Free subscription) | 17/07/2008
NEW YORK (MarketWatch) -- Baxter International said Thursday that it earned $544 million, or 85 cents a share, comapred to $413 million, or 65 cents a share in the year-ago period. The 2007 results include an after-tax restructuring charge of $46 million, 7 cents a share. Baxter's worldwide sales totaled $3.2 billion in the second quarter, an increase of 13%. Baxter is raising its financial outlook...
+Vote!
News & Information (Free subscription) | 17/07/2008
Company Posts Second Quarter EPS of $0.85 Per Diluted Share, An Increase of 31 Percent DEERFIELD, Ill., July 17 /PRNewswire-FirstCall/ — Baxter International Inc…….Read more
+Vote!
Seeking Alpha (Free subscription) | 16/07/2008
Baxter International (BAX) is expected to report Q2 earnings before market open on Thursday, July 17, with a conference call scheduled for 8:30 am ET. Guidance Analysts are looking for a profit of 82c on revenue of 3.05B. The consensus range is 80c to 82c for EPS, and revenue of $3.00B to $ 3.09B, according to First Call. Complete Story »
+Vote!
Business Wire (Free subscription) | 16/07/2008
CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting
